Using Drug Delivery Technology to Improve ADHD Therapies

from The Bio Report · host Levine Media Group

People with attention-deficit/hyperactivity disorder who use stimulants to treat the condition often face afternoon crashes and require the use of booster doses. Cingulate Therapeutics is using its proprietary drug delivery technology to target this $14 billion market with timed released formulations of commonly used ADHD drugs it is developing. We spoke to Shane Schaffer, CEO of Cingulate, about ADHD, the company drug delivery technology, and its clinical path forward.

Episode metadata supplied by the publisher feed · Published Nov 15, 2018

Embed this episode

Attribution link and audio player

NOW PLAYING

Using Drug Delivery Technology to Improve ADHD Therapies

0:00 23:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Bio Report?

This episode is 23 minutes long.

When was this The Bio Report episode published?

This episode was published on November 15, 2018.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!